What we do
Claris Ventures makes equity investments in early stage biopharma companies with a clear vision and solid scientific evidence.
We are fascinated by science and we are committed to help the best innovators in addressing strong unmet clinical needs, spanning from rare diseases to oncology, immunology and other life threatening disease areas.
We provide capital, competence and hands-on support to jump start clinical development programs and pursue value creation based on clinical evidence.
Team
Managing Partner
Managing Partner
Partner
Associate
Senior Analyst
Investment Committee
Investment Committee
Manilo Marocco
Investment Committee

Investment Committee
Independent Director
Advisor
Portfolio
Kither Biotech develops new drugs for incurable respiratory diseases
NeoPhore develops next-generation cancer immunotherapies
First-in-class anti-miR compounds for liver diseases and cancer
RNA-based therapies to induce cardiac regeneration
Innovative medicines for central nervous system disorders
Drug discovery platform to unveil new class of small-molecule degraders
Development of innovative compounds that prevent metastasis
Repron Therapeutics
Developing first-in-class therapeutics to silence transcriptional factors of oncogenes

Developing first-in-class therapeutics to silence transcriptional factors of oncogenes